Valsartan and Hydrochlorothiazide tablets will be produced at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
New Delhi: Zydus Cadila Saturday said the company has received final approval from the US health regulator to market Valsartan and Hydrochlorothiazide tablets, used to treat high blood pressure.
The company has got final approval from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 80mg/12.5 mg, 160 mtg/12.5 mg, 160 mg/25 mg, 320 mtg/12.5 mg, and 320 mg/25 mg, Zydus Cadila said in a BSE filing.
Valsartan belongs to a class of drugs called angiotensin receptor blockers (ARBs). It works by relaxing blood vessels so that blood can flow more easily. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems, while, Hydrochlorothiazide is a diuretic medication often used to treat high blood pressure and swelling due to fluid build up. Other uses include diabetes insipidus, renal tubular acidosis, and to decrease the risk of kidney stones in those with a high calcium level in the urine.
The drug will be produced at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
The Zydus group has more than 256 approvals and so far filed over 350 abbreviated new drug applications (ANDAs) since it started filings in 2003-04.